View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 13, 2022

FDA grants Orphan Drug Designation to Editas’ beta thalassemia therapy

The company intends to commence a Phase I/II trial of EDIT-301 in transfusion-dependent beta thalassemia patients this year.

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Editas Medicine’s experimental gene editing therapy, EDIT-301, to treat beta thalassemia.

EDIT-301 comprises CD34+ hematopoietic stem and progenitor cells obtained from patients and are edited at the gamma globin gene (HBG1 and HBG2) promoters by a AsCas12a nuclease.

It is being analysed to treat severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

The company intends to commence a Phase I/II clinical trial of EDIT-301 in transfusion-dependent beta thalassemia patients with dosing anticipated by the end of this year.

Editas Medicine chairman, president and CEO James Mullen said: “Beta thalassemia is a devastating disease that leads to severe anaemia, organ failure and premature death. 

“Preparations to initiate the Phase I/II clinical trial of EDIT-301, a potentially transformative medicine for people living with beta thalassemia, are underway, and we look forward to dosing the first patient in the clinical trial this year.”

Beta thalassemia is a common autosomal recessive condition and its mutations lower or hinder the expression of beta globin.

Inadequate production of beta globin causes ineffective production of red blood cells, compensatory extramedullary hematopoiesis and chronic hemolytic anaemia due to red blood cell destruction.

Earlier, EDIT-301 received a Rare Pediatric Disease Designation from the FDA to treat beta thalassemia and SCD.

It is presently being analysed in the RUBY clinical trial enrolling patients with severe sickle cell disease. 

In April 2019, Editas and BlueRock Therapeutics collaborated to discover, develop and manufacture of new drugs in oncology, neurology, cardiology and immunology areas.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU